Locatim (previously Serinucoli)
Locatim, oral solution for neonatal calves less than 12 hours of age
Table of contents
Overview
Locatim is a veterinary medicine used to reduce death in newborn calves caused by enterotoxicosis due to the bacterium Escherichia coli during the first days of life. Enterotoxicosis is a disease caused by the release of toxins in the body, with the main symptom being diarrhoea.
Locatim contains the active substance bovine concentrated lactoserum containing specific immunoglobulins G against E. coli F5 (K99) adhesin.
Authorisation details
Product details | |
---|---|
Name |
Locatim (previously Serinucoli)
|
Agency product number |
EMEA/V/C/000041
|
Active substance |
Bovine concentrated lactoserum containing specific immunoglobulins G against E. coli F5 (K99) adhesin
|
International non-proprietary name (INN) or common name |
Locatim, oral solution for neonatal calves less than 12 hours of age
|
Species |
Calves, neonatal less than 12 hrs of age
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI02AT01
|
Publication details | |
---|---|
Marketing-authorisation holder |
Biokema Anstalt
|
Revision |
15
|
Date of issue of marketing authorisation valid throughout the European Union |
29/03/1999
|
Contact address |
Pflugstrasse 12
Fürstentum 9490 Vaduz Liechtenstein |
Product information
09/09/2021 Locatim (previously Serinucoli) - EMEA/V/C/000041 - II/0018
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Therapeutic indication
Reduction of mortality caused by enterotoxicosis associated with E. coli F5 (K99) adhesin during the first days of life as a supplement to colostrum from the dam.